Clinical efficacy and safety: nervous system
HumanRegulatory and procedural guidanceResearch and developmentScientific guidelines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
The European Medicines Agency's scientific guidelines on the clinical evaluation of medicines used in nervous-system disorders help medicine developers prepare marketing authorisation applications for human medicines.
For a complete list of scientific guidelines currently open for consultation, see Public consultations.
Guidelines
- Clinical development of medicinal products for the treatment of autism spectrum disorder (ASD)
- Clinical development of medicinal products intended for the treatment of pain
- Clinical investigation of medicinal products for the treatment and prevention of bipolar disorder
- Clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis
- Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)
- Clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy
- Clinical investigation of medicinal products for the treatment of multiple sclerosis
- Clinical investigation of medicinal products for the treatment of obsessive compulsive disorder
- Clinical investigation of medicinal products for treatment of migraine
- Clinical investigation of medicinal products in the treatment of depression
- Clinical investigation of medicinal products in the treatment of epileptic disorders
- Clinical investigation of medicinal products in the treatment of Parkinson's disease
- Clinical investigation of medicinal products indicated for generalised anxiety disorder
- Clinical investigation of medicinal products indicated for panic disorder
- Clinical investigation of medicinal products indicated for the treatment of social anxiety
- Clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia
- Development of medicinal products for the treatment of alcohol dependence
- Development of medicinal products for the treatment of post-traumatic stress disorder
- Development of new medicinal products for the treatment of smoking
- Clinical investigation of medicines for the treatment of Alzheimer's disease
- Medicinal products for the treatment of insomnia
- Treatment of premenstrual dysphoric disorder